Drug Information

Drug (ID: DG01539) and It's Reported Resistant Information

• Name: CUDC-101
• Synonyms: CUDC-101; 1012054-59-9; CUDC 101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; CUDC101; UNII-1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; CHEMBL598797; 1A7Y9MP123; 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; CUDC-101, Free Base; SCHEMBL93769; MLS006010163; GTPL8894; AOB6495; DTXSID00143784; EX-A842; QCR-203; HMS3654C20; BCP01935; BDBM50307768; MFCD15528940; NSC800081; s1194; ZINC43196377; AKOS022526176; BCP9000556; CCG-264856; compound 8 [PMID: 20143778]; DB12174; NSC-800081; SB19287; NCGC00263177-01; NCGC00263177-05; NCGC00263177-12; 1313875-12-5; AC-28428; AS-16955; HY-10223; SMR004701272; FT-0665231; SW219934-1; X7526; J-000340; J-519062; Q27076925; Heptanamide, 7-[[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-hydroxy-
• Indication:
  In total 1 Indication(s)
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Phase 1; [1]
• Target: Epidermal growth factor receptor (EGFR); EGFR_HUMAN; [1]
• Formula: 12
• IsoSMILES: COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO
• InChI: InChI=1S/C24H26N4O4/c1-3-17-9-8-10-18(13-17)27-24-19-14-22(21(31-2)15-20(19)25-16-26-24)32-12-7-5-4-6-11-23(29)28-30/h1,8-10,13-16,30H,4-7,11-12H2,2H3,(H,28,29)(H,25,26,27)
• InChIKey: PLIVFNIUGLLCEK-UHFFFAOYSA-N
• PubChem CID: 24756910
• DrugBank ID: DB12174

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Epidermal growth factor receptor (EGFR) [1]

• Molecule Alteration: Missense mutation; p.T790M (c.2369C>T)
• Sensitive Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vivo Model: Female athymic mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Perkin-Elmer ATPlite assay
• Mechanism Description: The missense mutation p.T790M (c.2369C>T) in gene EGFR cause the sensitivity of CUDC-101 by aberration of the drug's therapeutic target

References

• Ref 1: CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activityCancer Res. 2010 May 1;70(9):3647-56. doi: 10.1158/0008-5472.CAN-09-3360. Epub 2010 Apr 13.